This is a routine procedural amendment to add a holding company entity. No material change to the deal economics or timeline. Monitor for the definitive proxy statement from XOMA Royalty for stockholder vote details and expected closing timeline.
Price Chart
Executive Summary
Ligand Pharmaceuticals filed an 8-K reporting Amendment No. 1 to its Merger Agreement with XOMA Royalty Corporation. The amendment adds XOMA Royalty Holdings Corporation (HoldCo) as a party to the agreement, a procedural step to facilitate the holding company reorganization structure for the acquisition. No financial terms, deal value, or changes to consideration were disclosed.
Key Financial Metrics
Key Facts
- Amendment No. 1 to the Agreement and Plan of Merger dated May 16, 2026
- Adds XOMA Royalty Holdings Corporation (HoldCo) as a party to the Merger Agreement
- HoldCo was formed on May 15, 2026, solely to effect a holding company reorganization under Nevada law
- No changes to financial terms, consideration, or closing conditions disclosed
- Original Merger Agreement was entered into on April 27, 2026
Financial Impact
No financial impact disclosed — amendment is procedural only
Risk Factors
- Transaction may fail to close if regulatory approvals or XOMA Royalty stockholder approval are not obtained
- Integration risks and potential for competing offers as noted in forward-looking statements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-228003 |
| Document: d86489dex21.htm | 0001193125-26-228003 |
| Document: 0001193125-26-228003-index-headers.html | 0001193125-26-228003 |
| Document: 0001193125-26-228003-index.html | 0001193125-26-228003 |
| Document: 0001193125-26-228003.txt | 0001193125-26-228003 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 18, 2026 23w ago | DEFA14A | — | awaiting T+5 | — | — |
May 18, 2026 23w ago | 8-K | — | awaiting T+5 | — | — |
Apr 30, 2026 25w ago | 8-K | — | awaiting T+5 | — | — |
Apr 27, 2026 26w ago | DEFA14A | $0.0400 $0.0500 | ▲ +25.00% | ▲ +24.32% | — |
Apr 27, 2026 26w ago | 8-K | $0.0400 $0.0500 | ▲ +25.00% | ▲ +24.32% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers